In veterinary pharmaceutical manufacturing, the powder designated as Duowei Jianwei Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions functions as a multi-analyte nutrient and digestive-function active constituent rather than as a single purified chemical entity. The material is supplied as a free-flowing, off-white to pale yellow powder with hygroscopic character, and its particle-size distribution is typically controlled so that not less than 95% passes through an 80-mesh (180 µm) sieve. The product identity is carried by the registered Chinese trade name and the veterinary-grade API statement; no harmonized alphanumeric model code appears in open export documentation. Where a model identifier is required for import or manufacturing records, the manufacturer’s veterinary drug registration number and the batch-specific certificate of analysis serve as the primary traceability keys. Because the exact quantitative composition is proprietary, pharmacopoeial identification is not a single monograph test but a multi-marker chromatographic profile. The powder is intended solely for incorporation into finished veterinary dosage forms: tablets, injections, capsules, powders, granules, premix, and solutions. Its specification philosophy therefore differs from that of a single-entity vitamin API: release criteria combine physical handling properties, microbial load, residual moisture, heavy-metal limits, and multi-analyte assay rather than a single thiamine or riboflavin titre.

Which release specifications and analytical methods define lot conformity?

Lot conformity for this veterinary-grade powder is established through a coordinated set of physical, chemical, and microbiological tests. Because the powder is hygroscopic, residual moisture is determined by oven drying at 105 °C to constant mass following the general procedure of ISO 6496:1999; a representative acceptance limit is not more than 5.0% w/w. Heavy-metal screening is performed by inductively coupled plasma mass spectrometry or atomic absorption after closed-vessel microwave digestion, using the methodological approach of ISO 13917:2002; typical release limits are not more than 10 mg/kg lead, 2 mg/kg arsenic, and 1 mg/kg cadmium. Microbiological acceptance follows the plate-count and pathogen-absence procedures given in ISO 4833-1:2013, ISO 21527-1:2008, and ISO 6579-1:2017. The powder is typically controlled to a total aerobic microbial count not exceeding 1000 CFU/g, a combined yeast and mould count not exceeding 100 CFU/g, and absence of Salmonella spp. and Escherichia coli. Identification and assay are performed by high-performance liquid chromatography with diode-array detection or tandem mass spectrometry against certified reference standards; because the product is multi-component, simultaneous multi-analyte separation is required to resolve overlapping spectral interferences. Bulk density is determined by a graduated-cylinder method with a typical release window of 0.55 to 0.75 g/mL. A representative specification matrix is shown below.

The absence of a harmonized pharmacopoeial monograph for this proprietary blend means that the exact assay limits for each marker must be obtained from the registration dossier or the manufacturer’s certificate of analysis. Published data for this specific configuration are limited; laboratory method transfer therefore requires matrix-matched calibration and forced-degradation verification because direct single-analyte ultraviolet methods frequently under-recover the multi-analyte fraction.

For tablet manufacturing, direct compression is generally unsuitable when the powder fraction exceeds 40% of the core weight because of low bulk flow and high dusting tendency. The preferred manufacturing route is wet granulation in a high-shear granulator or fluid-bed granulator with purified water or a 2–5% w/w povidone binder; the wet mass is dried at inlet air temperature 50–60 °C to a final granule moisture below 2.5% w/w. Dried granules are screened through a 16-mesh sieve and lubricated with 0.5–1.0% w/w magnesium stearate for not more than 5 min to avoid over-lubrication. Tablets are compressed on a rotary press with pre-compression force of 2–5 kN and main compression force of 8–20 kN; hardness is monitored at 60–90 N. Hard-capsule formulations are prepared by dry blending with 12–20% microcrystalline cellulose and 0.5–1.0% w/w magnesium stearate, followed by filling on a dosator or tamping-pin machine with a fill-weight variation controlled to ±5% per capsule. Powder and granule dosage forms intended for oral administration are produced by direct mixing or dry granulation through a roller compactor; the granule fraction between 16 mesh and 24 mesh is retained for final packaging. These processing windows are derived from equivalent veterinary multivitamin powders; batch-specific optimization remains mandatory because the proprietary carrier system can shift granulation endpoint.

For oral solutions and drinking-water formulations, the powder is dispersed in purified water at 20–25 °C under low-shear stirring; the solution is pre-filtered through a 45 µm nylon screen to remove the water-insoluble carrier fraction where present. The reconstituted oral solution should be protected from light and used within 24 h at 20–25 °C to limit microbial regrowth unless a preservative system has been validated. In feed-premix manufacturing, the powder is introduced by stepwise dilution: a 1:5 w/w initial blend with a carrier such as lactose monohydrate or corn-cob meal is prepared in a ribbon blender, then diluted to 1:25 and finally to the target inclusion rate of 0.1–0.5% w/w in complete feed. Mixing time is established by coefficient-of-variation sampling; a CV below 5% is typically required after not more than 10 min in a ribbon blender operating at the manufacturer’s specified speed. Segregation is controlled by maintaining blend fill volume below 50% of mixer capacity and by minimizing transfer height to the packaging hopper.

When parenteral administration is required, the handling envelope changes at the sterility and endotoxin threshold

The multi-use designation “for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions” does not imply that every batch is automatically suitable for injection. Parenteral use is permitted only when the manufacturer designates the injection-grade fraction and when the batch passes pyrogen and sterility testing. For injectable solutions, the powder is dissolved in Water for Injection at 20–25 °C with gentle agitation; the solution is clarified through a 0.45 µm membrane and sterile-filtered through a 0.22 µm PVDF or PES membrane into depyrogenated vials. The final solution should be visually inspected for particulate matter; subvisible particle testing by light-obscuration instrument is applied where required by the veterinary product registration. Bacterial endotoxin control follows the Limulus amebocyte lysate method; a limit of not more than 0.5 EU/mg is commonly applied to parenteral-grade veterinary powders, although the registered limit must be taken from the product dossier. If insoluble carrier agents or suspending excipients are present, the standard premix fraction is inappropriate for intravenous or intramuscular administration, and published data for this specific configuration is limited. Autoclaving of reconstituted multivitamin solutions is generally avoided because of thermal degradation of heat-labile vitamins; therefore, aseptic filtration rather than terminal sterilization is the preferred manufacturing route when permitted by the manufacturing authorization.

In comparison with single-entity vitamin APIs such as thiamine hydrochloride, riboflavin, or cyanocobalamin concentrates, the Duowei Jianwei Powder Veterinary Grade API displays a fundamentally different analytical and formulation profile. Single-entity APIs are characterized by one pharmacopoeial monograph, one principal active peak, and a narrow impurity profile. The multi-analyte nature of this product requires simultaneous multi-analyte HPLC-DAD or LC-MS/MS methods, because overlapping ultraviolet chromophores can produce false-positive identity results if single-wavelength detection is used. The matrix also influences dissolution: a single-vitamin tablet may release ≥80% of the declared label claim within 30 min under standard veterinary dissolution conditions, whereas a multi-analyte blend may require a dissolution profile over 60–120 min and matrix-specific release criteria. Compared with non-API multivitamin premixes intended only for feed fortification, the veterinary-grade API is controlled to tighter microbial and heavy-metal limits and is supplied without final feed-carrier dilution. It is also not interchangeable with human-grade multivitamin powders: human-grade materials are manufactured under human GMP and often tested against pharmacopoeial general chapters for elemental impurities; their excipient systems and residual solvent profiles may not be compatible with veterinary dossiers, and their use in food-producing animals may violate residue and withdrawal regulations. The summary comparison below illustrates the principal differentiating characteristics.

Stability-limiting incompatibilities and storage thresholds

The powder is hygroscopic and oxidation-sensitive; storage is therefore controlled in sealed aluminium-foil or HDPE containers with desiccant at or below 25 °C and relative humidity below 60%. Once the original container is opened, the material should be re-sealed under dry conditions and used within the manufacturer’s stated in-use period. Pre-drying at 40–45 °C for 2–4 h may be required if exposure to relative humidity above 60% has occurred before blending. The product should not be dry-mixed with strong oxidizing agents, highly alkaline ingredients, or undiluted choline chloride in high-moisture premixes, because these conditions accelerate vitamin degradation and generate caking. Direct contact with reducing sugars in wet granulation can also promote Maillard-type degradation of amine-containing constituents; where such excipients are required, a non-aqueous granulation or immediate drying step is preferred. For liquid dosage forms, pH is maintained according to the registered formulation; alkaline pH above 8.0 accelerates degradation of heat-labile vitamins, and therefore pH adjustment is validated rather than assumed from single-entity vitamin data. Because published data for this specific proprietary blend are limited, accelerated stability studies at 40 °C / 75% RH following VICH GL3 principles remain the standard method for establishing batch-specific shelf-life and in-use stability.